DryLabz GmbH

Based in Switzerland, DryLabz GmbH operates as a healthcare technology company focused on enhancing diagnostic processes through the integration of in-vitro tests with data science and artificial intelligence. DryLabz GmbH specializes in healthcare diagnostics, merging innovative technology with clinical practices. The company raised EUR 100,000 in pre-seed funding on March 17, 2025, from investor Antler. Headquartered in Basel, Switzerland, DryLabz operates primarily in the European market, with plans for future expansion.

Details about the founder and their previous ventures are currently unavailable. DryLabz GmbH specializes in integrating in-vitro diagnostic tests with medical records, data science, and artificial intelligence to enhance healthcare delivery. Their primary offerings focus on delivering personalized and efficient diagnostic solutions that allow healthcare providers, including physicians, nurses, and laboratory experts, to make informed clinical decisions. By leveraging data analytics, DryLabz aims to transform fragmented healthcare data into actionable insights, thereby improving patient outcomes and enabling healthcare professionals to dedicate more time to patient care.

The company's solutions are designed for a diverse clientele, including healthcare facilities, laboratory experts, health insurers, and diagnostics manufacturers, ensuring a comprehensive approach to improving healthcare delivery. DryLabz operates primarily in European markets, with potential expansion into other regions, reflecting its commitment to advancing diagnostics on a broader scale. The revenue model of DryLabz GmbH is structured around B2B partnerships and collaborations within the healthcare ecosystem, including hospitals, laboratories, and health insurers. Transactions typically involve the integration of DryLabz's diagnostic solutions into existing clinical workflows, with clients entering into subscription agreements or service contracts that outline ongoing support and updates.

These agreements facilitate a steady revenue stream as healthcare providers adopt DryLabz’s technology to enhance their diagnostic capabilities. The company’s flagship products, which include proprietary diagnostic platforms and analytics tools, serve to meet the needs of modern healthcare delivery while maintaining competitive pricing structures aligned with industry standards. In March 2025, DryLabz GmbH raised EUR 100,000 in funding to accelerate its growth. Future initiatives include the development of new diagnostic products and potential expansion into additional European markets, though specific timelines for product launches or market entries are yet to be detailed.

This funding will support these strategic initiatives aimed at scaling their innovative solutions within the healthcare sector.